Detection Technology (DETEC) investor relations material

Executive summary

• Q2 2026 net sales increased 5.1% year-on-year to EUR 25.6 million, with H1 sales up 9.1% to EUR 50.9 million, driven by strong medical and TFT growth, while industrial and security segments declined due to weak demand in China.

• EBITA reached EUR 1.8 million in Q2 (7.1% margin) and EUR 4.2 million in H1 (8.2% margin), reflecting operational improvements.

• Medical segment grew 21% in Q2, with global CT demand and new TFT deliveries; industrial fell 6%, security dropped 8%.

• TFT product sales expanded, now 10% of revenues, with launches across all regions and increased order backlog.

• Profitability improved, supported by favorable product mix and operational enhancements.

Financial highlights

• Q2 EBITA was EUR 1.8 million (7.1% margin); H1 EBITA reached EUR 4.2 million (8.2% margin).

• Q2 earnings per share were EUR 0.11; H1 EPS was EUR 0.24.

• Cash flow from operations was negative: EUR -0.6 million in Q2 and EUR -4.0 million in H1, mainly due to inventory increases.

• Investments in H1 totaled EUR 3.7 million, focused on R&D and production equipment.

• Dividend of EUR 4.4 million paid in H1 2026.

Outlook and guidance

• Net sales expected to grow year-over-year in Q3 and Q4 2026, with medical and industrial applications projected to increase and security to decline due to weak Chinese demand.

• Medium-term targets: annual sales growth of at least 10%, EBITA margin of 15%, and dividend payout of 30–60%.

• Order backlog shows growth in all regions.